Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 2, 2006, Pages 120-122

  Resch, B ^a   Gusenleitner, W ^a   Muller W D ^a   Haas, J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD HOSPITALIZATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEWBORN INTENSIVE CARE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; SEASONAL VARIATION; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; AUSTRIA; COHORT STUDIES; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEASONS;

EID: 33644670729     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0082-y     Document Type: Article

References (10)

1. McCormick MC, Shapiro S, Starfield BH (1980) Rehospitalization in the first year of life for high-risk survivors. Paediatrics 66:991-999
2. American Academy of Paediatrics (1998) Prevention of respiratory syncytial virus infections: indications for use of palivizumab and update on the use of RSV-IGIV. Paediatrics 102:1211-1216
3. Zaknun D, Resch B, Jürgenssen O, et al (2001) Prevention of respiratory syncytial virus (RSV) infection in preterm infants with palivizumab (Synagis). Monatsschr Kinderheilkd 149:176-178
4. Resch B, Gusenleitner W, Mandl C, Müller W (2000) Epidemiology of respiratory syncytial virus infection in southern Austria. Pediatr Infect Dis J 9:587-588
5. Groothuis JR, Simoes EAF, Levin MJ, and the RSVIG Study Group (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524-1530
6. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, for the Munich RSV Study Group (2003) Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:230-236
7. Simoes EAF, Groothuis JR (2002) Respiratory syncytial virus prophylaxis the story so far. Respir Med 96 (Suppl B):15-24
8. Arnold SR, Wang EEL, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 18:866-869
9. Parnes C, Guillermin J, Habersang R, et al (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the palivizumab outcome registry. Pediatr Pulmonol 35:484-489
10. Sáez-Llorens X, Castaño E, Null D, et al (1998) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia: the MEDI-493 Study Group. Pediatr Infect Dis J 17:787-791